uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
09 juil. 2024 07h05 HE | uniQure Inc.
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the...
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
03 juin 2024 07h05 HE | uniQure Inc.
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s...
Harness Therapeutics appoints Leading World Experts in Neurodegenerative Diseases to its Scientific Advisory Board (SAB)
30 mai 2024 07h00 HE | Harness Therapeutics
Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK, May 30, 2024:...
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
19 déc. 2023 07h05 HE | uniQure Inc.
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural...
Huntington's Disease Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Prilenia, Neurocrine, Annexon, SOM, Vaccinex, Sage, UniQure, Wave life sciences, Takeda, Medesis
01 nov. 2023 13h00 HE | DelveInsight Business Research LLP
New York, USA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Huntington's Disease Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Prilenia, Neurocrine, Annexon,...
Transparency Market Research
Digital Brain Health Market Predicted to Reach US$ 382.9 billion by 2031, Growing at a 7.3% CAGR Says, Transparency Market Research
26 oct. 2023 04h33 HE | Transparency Market Research
Wilmington, Delaware, United States, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The digital brain health market was valued at US$ 184.7 billion in 2021. The market is...
Transformative Research Award Recipients
Hereditary Disease Foundation Announces Recipients of Inaugural Transformative Research Award
04 oct. 2023 14h38 HE | Hereditary Disease Foundation
New York, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The Hereditary Disease Foundation has announced that the  recipients of its first Transformative Research Awards are two teams - one led by Beverly...
Figure 1. Treatment with pepinemab in combination with KEYTRUDA appears to induce formation of highly organized lymphoid structures in tumors that correlate with disease control.
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
26 sept. 2023 08h00 HE | Vaccinex, Inc.
"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer’s Disease...
Change in Total Motor Score
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
21 juin 2023 07h05 HE | uniQure Inc.
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural...
rumi logo.png
Rumi Scientific Announces Data Demonstrating Disease Modifying Effect of BRD9 Inhibition in a Huntington’s Disease Animal Model
26 avr. 2023 07h05 HE | Rumi Scientific, Inc.
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases discovered using its high throughput organoid phenotypic...